Aplastic anemia is a rare and serious blood disorder in which your bone marrow fails to produce enough new blood cells. Unlike typical anemia, which only involves red blood cells, aplastic anemia reduces all three types of blood cells simultaneously: red blood cells, white blood cells, and platelets. This across-the-board drop, called pancytopenia, is what makes the condition particularly dangerous and distinguishes it from more common forms of anemia.
What Happens Inside the Bone Marrow
Your bone marrow contains stem cells that act as the body’s blood cell factory. These stem cells continuously divide and mature into red blood cells (which carry oxygen), white blood cells (which fight infection), and platelets (which stop bleeding). In aplastic anemia, these stem cells are damaged or destroyed, and the marrow gradually fills with fat instead of producing healthy blood cells.
The most common cause of this damage is the body’s own immune system turning against the marrow. Specific immune cells release inflammatory signals that trigger the stem cells to self-destruct. This autoimmune attack resembles the kind of immune response the body mounts against viruses, but instead it’s directed at healthy marrow tissue. In other cases, the stem cells themselves become defective, losing their ability to replicate or mature properly. Shortened telomeres, the protective caps on chromosomes, can also shorten the lifespan and function of these stem cells over time.
Known Causes and Triggers
In most cases, aplastic anemia is acquired, meaning it develops during a person’s lifetime rather than being present at birth. The single most common cause is an autoimmune attack on bone marrow stem cells. But a range of environmental and medical triggers can also set the disease in motion:
- Toxic chemical exposure. Benzene (found in gasoline), pesticides, insecticides, herbicides, organic solvents, and paint removers have all been linked to aplastic anemia. Removing the exposure can sometimes allow recovery.
- Medications. Certain antibiotics, particularly chloramphenicol, and gold compounds used for rheumatoid arthritis are known triggers.
- Viral infections. Some viruses can directly damage bone marrow, including hepatitis viruses and others that affect marrow function.
- Radiation and chemotherapy. These cancer treatments kill rapidly dividing cells, including healthy stem cells. Aplastic anemia caused by cancer treatment is sometimes temporary.
- Pregnancy. Rarely, pregnancy can trigger the condition, though it sometimes resolves after delivery.
In a significant number of cases, no clear trigger is ever identified. These are labeled idiopathic, meaning the cause remains unknown even after thorough evaluation.
Inherited Forms: Fanconi Anemia
A small percentage of aplastic anemia cases are inherited rather than acquired. The best-known inherited form is Fanconi anemia, caused by mutations in any of more than 20 genes. About 80 to 90 percent of Fanconi anemia cases involve mutations in just three of those genes. The condition is typically inherited in a recessive pattern, meaning a child must receive a defective copy from both parents.
Fanconi anemia looks quite different from acquired aplastic anemia. Roughly 90 percent of affected individuals develop bone marrow failure, but they also tend to have physical features that appear early in life: short stature, irregular skin pigmentation (such as café-au-lait spots), malformed thumbs or forearms, small head size, and sometimes abnormalities in the eyes, kidneys, or reproductive organs. People with Fanconi anemia also face a significantly elevated risk of acute myeloid leukemia and certain solid tumors, particularly head and neck cancers. These features help doctors distinguish inherited from acquired forms, which is important because treatment strategies differ.
Symptoms to Recognize
Because aplastic anemia reduces all three blood cell lines, it produces a wide range of symptoms that can develop gradually or come on suddenly. Low red blood cells cause fatigue, weakness, shortness of breath, and pale skin. Low white blood cells leave you vulnerable to frequent or severe infections, fevers that don’t resolve easily, and slow recovery from illness. Low platelets lead to easy bruising, prolonged bleeding from cuts, nosebleeds, bleeding gums, and tiny red dots on the skin called petechiae.
Many people first notice extreme, unexplained fatigue or find that minor cuts bleed far longer than expected. The combination of these symptoms, especially fatigue plus unusual bruising plus recurrent infections, is what typically prompts the blood tests that reveal the problem.
How It’s Diagnosed
A standard blood test (complete blood count) usually provides the first clue by showing low numbers across all three cell types. But confirming aplastic anemia requires a bone marrow biopsy, in which a small sample of marrow is extracted, usually from the hip bone, and examined under a microscope. In aplastic anemia, the marrow appears noticeably emptier than normal, with fat replacing the tissue that should be producing blood cells.
Doctors classify the severity based on how low the blood counts have dropped. Severe and very severe cases are defined by specific thresholds in neutrophil counts (a key type of white blood cell), platelet levels, and reticulocyte counts (immature red blood cells). This classification directly determines treatment urgency and approach. Additional testing helps rule out other conditions that can mimic aplastic anemia, such as certain leukemias or vitamin deficiencies.
Treatment Options
Treatment depends on severity, the patient’s age, and whether a suitable donor is available for a bone marrow transplant.
Bone Marrow Transplant
For younger patients with severe disease who have a matched sibling donor, a bone marrow (stem cell) transplant is generally the preferred treatment. This replaces the damaged marrow with healthy donor stem cells that can rebuild the blood cell factory from scratch. Transplant outcomes are best in children and young adults, and outcomes decline with age due to higher rates of complications. After transplant, patients need to follow a careful recovery plan, including eating a healthy diet and taking precautions against infection while the new marrow establishes itself.
Immunosuppressive Therapy
For patients who don’t have a matched donor or who are older, immunosuppressive therapy is the standard approach. This typically involves a combination of two medications: one that suppresses the immune cells attacking the marrow (antithymocyte globulin, given intravenously over several days) and another taken orally for a year or longer to keep the immune system in check (cyclosporine). This combination produces a response in roughly 50 to 60 percent of patients, with about 60 percent overall survival at one year. In one study, 68 percent of patients became transfusion-independent by two years, with children responding better than adults.
The response to immunosuppressive therapy is gradual. Blood counts may take weeks to months to improve, and patients often need regular blood transfusions and infection management during that period.
Living With Aplastic Anemia
When your white blood cell count is very low, everyday activities carry infection risks that healthy people never think about. Food safety becomes especially important. You should fully cook all meat, fish, and eggs, avoid raw foods, skip fruits and vegetables you can’t peel, and stay away from unpasteurized dairy products and juices. These precautions reduce exposure to bacteria that a weakened immune system can’t fight off effectively.
Beyond diet, daily life with aplastic anemia often involves avoiding crowds and sick contacts during periods of low counts, being vigilant about any signs of infection (even a low-grade fever can signal a serious problem), and limiting activities that could cause injury and bleeding when platelets are low. Many patients require regular blood and platelet transfusions to manage symptoms until treatment takes effect.
Long-Term Outlook and Risks
Aplastic anemia is treatable, and many patients achieve remission or significant improvement, particularly with early and aggressive treatment. However, the disease carries long-term risks even after successful treatment. Approximately 15 percent of patients with acquired aplastic anemia develop myelodysplastic syndrome (a pre-leukemia condition) or acute myeloid leukemia within 10 years. This risk means that even patients who respond well to treatment need ongoing monitoring with regular blood tests for years afterward.
Relapse is also possible after immunosuppressive therapy, and some patients require additional rounds of treatment. Those who receive a bone marrow transplant face their own set of long-term considerations, including the possibility of graft complications and the effects of the conditioning treatments used to prepare the body for transplant. The key takeaway is that aplastic anemia requires not just initial treatment but sustained follow-up care to catch complications early.